Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Vivet Therapeutics S.A.S. and Pfizer Inc. announced today that they have entered into a manufacturing agreement under which Pfizer's gene therapy manufacturing…
Pfizer will supply clinical-stage manufacturing for Vivet Therapeutics' Wilson disease gene therapy VTX-801 from its Sanford Burnham Prebys Chapel Hill…
Pfizer's gene therapy manufacturing facility in Chapel Hill, North Carolina, will produce clinical material for VTX-801, Vivet Therapeutics' AAV-based…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Vivet Therapeutics and Pfizer entered a manufacturing agreement under which Pfizer's Chapel Hill, NC facility supplied clinical material for the GATEWAY Phase 1/2 trial of VTX-801 (AAV gene therapy for Wilson disease). Builds on Pfizer's 2019 minority equity stake and exclusive option to acquire Vivet. Terms not disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Vivet Therapeutics S.A.S. (this deal) | 2020 | — | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2020 deals · Pfizer Inc. deals · Rare Disease deals